5 months in and metformin is still the thing I get wrong
5 months in and metformin is still the thing I get wrong. This is a description of what happened to me and not a plan for anybody else. Numbers, in the order they matter: 5 months. The three numbers, and what each one can and cannot tell you. A1c is an average over about three months, weighted to the recent weeks. It…
On hypoglycaemia, because the risk gets attributed to the wrong thing constantly.
Incretin-based agents stimulate insulin secretion in a glucose-dependent way: the effect scales with glycaemia rather than acting unconditionally. That is why monotherapy risk is low. Where risk rises substantially is in combination with agents that lower glucose independently of the current level.
Which means the question "does this cause hypos" is not answerable without knowing the rest of the regimen — and that the person who can answer it is the one who wrote the regimen. Nothing on this board is a substitute for that conversation, and the good threads here end by saying so.
The diabetes and obesity programmes are separate, with different populations and different primary endpoints. Reading a result across from one to the other is not a comparison.
A1c is a three-month average and it lags everything
Correction: that trial is the diabetes programme and the figure you quoted is its glycaemic endpoint, not a weight result.
nothing here replaces the person managing your diabetes
the fasting number is the one people fixate on and it moves last
A1c is a three-month average and it lags everything
Agreed, and the glucose-dependence point is the reason the risk profile reads the way it does.